Analyst Research

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: Reuters Investment Profile
$20.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: New Constructs, LLC
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Alkermes announces initiation of phase 1 clinical study of ALKS 7106 for treatment of pain


Tuesday, 26 Aug 2014 07:00am EDT 

Alkermes PLC:Says initiation of phase 1 clinical study of ALKS 7106, proprietary, novel, oral, small-molecule drug candidate for the treatment of pain.The randomized, double-blind, placebo-controlled study will evaluate the safety, tolerability and pharmacokinetics of ALKS 7106 in approximately 80 healthy, male adults.ALKS 7106 represents a new class of analgesic agents in development at Alkermes: potent opioid modulators designed for treatment of pain with intrinsically low potential for abuse and overdose death - two liabilities associated with opioid analgesics.ALKS 7106's potential attributes derive from its intrinsic mechanism of action in the brain rather than through the use of abuse-deterrent technologies or formulations.This phase 1, randomized, double-blind, placebo-controlled, single-ascending-dose, multi-cohort, four-week study will evaluate the safety, tolerability and pharmacokinetics of ALKS 7106 administered orally in about 80 healthy, male adults.Results from this phase 1 study are expected in the first half of 2015. 

Company Quote

62.79
-0.89 -1.40%
17 Apr 2015